Cantargia AB

Research Cantargia AB (CANTA) on Bullrun: valuation model: 151.2% undervalued, market cap SEK 538.99M, P/E 3.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCANTA
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Valuation signal151.2% undervalued
• Market capSEK 538.99M
• P/E3.4
• Financial periodQ4 2025
• RevenueSEK 8.01M
• Net income-SEK 32.34M
• Free cash flow-SEK 52.64M

Valuation Snapshot

Bullrun's latest valuation model marks Cantargia AB as 151.2% undervalued; latest market cap is SEK 538.99M; P/E is 3.4.

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer;

Frequently asked questions

Is Cantargia AB overvalued or undervalued?

Bullrun's valuation model currently marks Cantargia AB as 151.2% undervalued.

What is Cantargia AB's market cap?

Cantargia AB's market capitalization is SEK 538.99M.

What is Cantargia AB's P/E ratio?

Cantargia AB's price-to-earnings (P/E) ratio is 3.4.

What does Cantargia AB do?

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.